https://www.selleckchem.com/pr....oducts/cd38-inhibito
Neuroblastoma (N is the most common extracranial solid tumor among children. The 5-year event-free survival rate for high-risk (HR) NB is still poor, especially for patients with advanced NB with gene amplification. Chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for HR-NB. A 55-month-old boy with stage IV HR-NB received 4th-generation CAR-T cells that target disialoganglioside GD2, as consolidation maintenance treatment after intensive chemotherapy, surgery, and autologous stem-cell transplantation. As of
Like
Comment
Share
